卡维迪洛尔与梅托普罗罗尔在左心室辅助器件患者中的有效性:TrinetX分析
Karldon I Nwaezeapu1, Godbless Ajenaghughrure2, Ekow Essien3
1Internal Medicine, Trinity Health Ann Arbor Hospital, Ypsilanti, USA.
Cureus
|August 11, 2025
概括
左心室辅助器械 (LVAD) 患者使用卡维迪与较低的死亡率和较少的心脏事件有关. 然而,carvedilol也显示心力衰竭恶化和脏问题增加,需要小心选择患者.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- β抑制剂对于心力衰竭管理至关重要.
- 在机械循环支持患者中对β-阻断剂的比较数据有限.
- 这项研究比较了左心室辅助器件 (LVAD) 患者的卡维迪醇和甲醇.
研究的目的:
- 为了在LVAD患者中比较卡维迪洛和梅托普罗洛的临床结果.
- 评估卡维迪洛尔与美托普罗罗尔在降低死亡率和不良事件方面的有效性.
- 在LVAD接受者中告知β-阻断剂选择.
主要方法:
- 使用TriNetX研究网络进行的回顾性队列研究.
- 5,166名患者的倾向性得分匹配,每个人都接受了卡维迪洛尔或美托普罗洛尔.
- 一年内所有原因死亡率和二次结果的分析.
主要成果:
- 卡维迪醇组的全因死亡率较低 (15.4%与17.0%相比),心脏骤停,心脏性休克,败血症和心房动减少.
- 较高的心力衰竭恶化率 (71.3%与65.9%) 和急性损伤率 (31.8%与28.1%) 被观察到与carvedilol.
- 病综合征没有显著差异;心室动脉短心率没有临床意义.
结论:
- 在LVAD患者中,卡维迪醇与较低的死亡率和较少的心血管并发症有关,而不是梅托普罗罗尔.
- 心力衰竭恶化和脏并发症的更高率需要个性化的患者选择.
- 需要进一步的前性研究来证实这些发现,并优化β-阻断剂的选择.
关键词:
晚期心力衰竭是什么意思贝塔抑制剂 贝塔抑制剂卡尔维迪醇是一种心脏衰竭是因为心脏衰竭.左心室辅助器件 (lvad) 是一种辅助器件.拉维德是什么意思 拉维德机械循环支持 机械循环支持甲托普罗罗醇是一种甲托普罗醇.死亡率 死亡率更多相关视频
07:39Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
Published on: August 16, 2021
3.7K
12:45Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
Published on: December 11, 2017
10.6K
相关概念视频
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
508
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
508
01:29Cardiomyopathy V: Interprofessional Care
33
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
33
01:31Adrenergic Antagonists: ɑ and β-Receptor Blockers
603
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
603
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27